查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715479

製药连续製造市场（按组件、技术类型、配方、最终用户、治疗领域和应用）—2025-2030 年全球预测

Pharmaceutical Continuous Manufacturing Market by Component, Technology Type, Formulations, End-user, Therapeutic Area, Applications - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2023 年製药连续生产市场价值将达到 15.8 亿美元，2024 年将成长至 17.6 亿美元，到 2030 年将达到 35.1 亿美元，复合年增长率为 12.08%。

主要市场统计数据
基准年2023年 15.8亿美元
预计2024年 17.6亿美元
预测年份 2030 35.1亿美元
复合年增长率（%） 12.08%

在当今充满活力的製药环境中，连续製造的出现正在重塑传统模式。这种创新方法将尖端的自动化流程、先进的控制和精简的操作结合在一起，开创了生产效率和品质的新时代。随着全球製药业面临产品设计和监管要求日益复杂的情况，连续生产因其提供毫不妥协的一致性和即时製程监控而脱颖而出。

组织正在逐渐将重点从批次转移到连续操作，以实现更大的扩充性、缩短生产时间和资源最佳化。製造实践的演变不仅受到市场需求的驱动，也受到对强大、灵活和有弹性的供应链的需求的驱动。在此背景下，确保品质合规性同时维持高生产吞吐量是连续製造有效解决的平衡行为。

尖端数位解决方案与传统生产方法的结合创造了一个创新与可靠性相结合的肥沃平台。透过投资这种变革性方法，公司不仅可以降低营运成本，还可以为改善流程分析和永续製造实践打开大门。在全球市场中，持续製造的承诺不仅限于业务效率；它代表了医药产品概念化、开发和交付方式的模式转移。

重新定义製药业格局的转型

在技​​术、法规和市场需求融合的推动下，製药业正在经历重大转型。从传统批量生产向连续生产的转变不仅仅是操作上的升级；这是一场从根本上改变公司设计和执行生产策略方式的革命。

该行业的关键转变包括更加重视提高流程可靠性、智慧技术整合以及即时监控和自适应控制系统。随着世界各地的监管机构越来越重视品质源自于设计 (QbD) 和流程分析技术 (PAT)，连续製造流程完美地融入了这个前瞻性框架。结果是，对品质问题的反应更加灵活，对需求波动的反应更加适应，并且对流程检验和改进的方法更加创新。

市场领导者正在利用这些变化，充分利用连续製造的潜力来创建能够提供一致的产品品质、更短的生产週期和降低的营运风险的製造环境。这种结构转型是由对卓越的不懈追求所驱动的，持续改进和技术整合是每个决策的核心。公司不仅在实现生产线现代化，而且还在重塑整个供应链以满足不断变化的市场需求。

数位创新与既定生产通讯协定的融合正在成为变革的催化剂，为各行业的效率、敏捷性和弹性设定新的基准。这种转变并不局限于单一领域，而是渗透到业务、法规和市场策略中，为製药製造业创造更具竞争力和永续性的未来。

不断发展的市场提供了关键的细分洞察

细緻地了解市场区隔对于驾驭连续製造领域至关重要。細項分析从各个方面揭示市场，每个维度都为生产创新和业务成功的市场驱动因素提供了宝贵的见解。基于组件的研究强调了设备、服务以及软体和控制解决方案的多种方法。在此框架内，设备研究进一步分为搅拌机、进料机、製粒机和反应器等特定领域，确保製造商瞄准无缝生产流程所需的最关键设备。

我们对技术类型的关注引入了另一层差异：分离整合连续和半连续製造系统。这种区别至关重要，因为它反映了频谱技术成熟度和适应特定操作要求的能力。同时，透过剂型分析（液体、半固态和固态）为製造商提供了全面的视角，以评估各种产品类型的连续生产流程的适用性和灵活性。

根据最终用户活动对市场进行细分进一步深化了这项洞察，使我们能够区分契约製造组织和製药公司。每个部分都有自己的要求和性能基准，围绕着品质、扩充性和成本效益进行对话。此外，透过考虑循环系统疾病、中枢神经系统疾病、感染疾病、代谢疾病和肿瘤等治疗领域，细分更加深入，展示了产品特异性如何推动製造业创新。

最后，仔细研究原料药、生物製药和口服药物等应用，凸显了将製造技术与产品的最终用途和市场需求结合的重要性。这些细分见解不仅突显了连续製造的多面性，而且有助于指南日益复杂的市场环境中的策略决策。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球慢性病盛行率不断上升
      • 对高效率、可靠的药品生产系统的需求日益增加
      • 鼓励製药业采用连续生产方式的监管支持和奖励
    • 限制因素
      • 启动成本高，且缺乏经过适当训练的专业人员
    • 机会
      • 製造技术的进步实现了即时数据监控和流程优化
      • 传统製造技术开发的投资和资金激增
    • 任务
      • 传统製造工艺的技术限制和复杂性
  • 市场区隔分析
    • 组件：製药连续生产的效率－用于连续製药生产的软体和控制解决方案
    • 技术类型：利用整合连续生产系统实现高品质产品并节省时间和成本
    • 配方：药物输送系统的个人化正在增加固态剂型的使用。
    • 最终用户：製药公司采用此方法可提高生产效率和控制力。
    • 治疗领域：增加感染疾病的使用以提高製药生产的灵活性和产能
    • 用途：扩大口服药物的使用，以提高药物配方的一致性和品质
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 药品连续生产市场（依组件）

  • 装置
    • 混合器
    • 进纸器
    • 製粒机
    • 核子反应炉
  • 服务
  • 软体和控制解决方案

7. 医药连续製造市场（依技术类型）

  • 整合连续生产系统
  • 半连续生产系统

8. 药品连续生产市场（依配方）

  • 液体製剂
  • 半固态製剂
  • 固态製剂

第九章。医药连续製造市场（按最终用户）

  • 契约製造组织
  • 製药公司

第 10 章 药品连续製造市场（依治疗领域）

  • 心血管疾病
  • 中枢神经系统疾病
  • 感染疾病
  • 代谢紊乱
  • 肿瘤学

第 11 章 医药连续製造市场（依应用）

  • 活性药物成分
  • 生物製药
  • 口服药物

12.美洲药品连续製造市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区製药连续生产市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14.欧洲、中东和非洲製药连续生产市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • ABB Ltd
  • Amazon Web Services, Inc.
  • Capgemini SE
  • Chemtrix BV by AGI Group
  • Continuus Pharmaceuticals
  • Coperion GmbH
  • Corning Incorporated
  • Emerson Electric Co.
  • Fette Compacting
  • GEA Group AG
  • Gebruder Lodige Maschinenbau GmbH
  • Glatt GmbH
  • Honeywell International, Inc.
  • Hosokawa Micron Corporation
  • IMA Group
  • Korsch AG
  • LB Bohle Maschinen und Verfahren GmbH
  • Pall Corporation by Danaher Corporation
  • Repligen Corporation
  • Rockwell Automation Inc.
  • Scott Equipment Company
  • Siemens AG
  • Syntegon Technology GmbH
  • Thermo Fisher Scientific Inc.
Product Code: MRR-030EE48515D8

The Pharmaceutical Continuous Manufacturing Market was valued at USD 1.58 billion in 2023 and is projected to grow to USD 1.76 billion in 2024, with a CAGR of 12.08%, reaching USD 3.51 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 1.58 billion
Estimated Year [2024] USD 1.76 billion
Forecast Year [2030] USD 3.51 billion
CAGR (%) 12.08%

In today's dynamic pharmaceutical environment, the emergence of continuous manufacturing is reshaping traditional paradigms. This innovative approach integrates state-of-the-art automated processes, advanced controls, and streamlined operations to usher in a new era of production efficiency and quality. As the global pharmaceutical industry confronts increasing complexity in product design and regulatory expectations, continuous manufacturing stands out by providing uncompromised consistency and real-time process monitoring.

Organizations are progressively shifting their focus from batch processing to continuous operations to achieve enhanced scalability, reduced production times, and better resource optimization. The evolution in manufacturing practices is not merely a response to market demand-it is also driven by the need for a robust, agile, and resilient supply chain. In this landscape, ensuring quality compliance while maintaining high production throughput is a balancing act that continuous manufacturing addresses effectively.

The integration of cutting-edge digital solutions with traditional production methodologies has created a fertile platform where innovation meets reliability. As companies invest in this transformative methodology, they not only stand to reduce operational costs but also open doors to improved process analytics and sustainable manufacturing practices. In a well-connected global market, the promise of continuous manufacturing extends beyond operational efficiency; it represents a paradigm shift in how pharmaceutical products are conceptualized, developed, and delivered.

Transformative Shifts Redefining the Pharmaceutical Landscape

The pharmaceutical industry is experiencing a monumental shift driven by the convergence of technology, regulation, and market demands. The transformation from traditional batch production methods to continuous manufacturing represents more than an operational upgrade; it is a revolution that is fundamentally altering the way companies design and execute their production strategies.

Key shifts in the industry include the drive for increased process reliability, the integration of smart technologies, and an enhanced focus on real-time monitoring and adaptive control systems. As regulatory bodies around the world increasingly emphasize quality by design (QbD) and process analytical technology (PAT), the continuous manufacturing process is aligning perfectly with this forward-thinking framework. The result is an industry that is more nimble in responding to quality issues, more adaptive in managing fluctuations in demand, and more innovative in its approach to process validation and improvement.

Market leaders are capitalizing on these changes by embracing the full potential of continuous manufacturing, thereby creating manufacturing environments that offer consistent product quality, reduced production cycle times, and lower operational risks. This structural transformation is propelled by the relentless pursuit of excellence, where continuous improvements and technology integration are at the heart of every decision. Companies are not only modernizing their production lines but also reinventing their entire supply chain to meet the demands of an ever-changing marketplace.

The fusion of digital innovation with established production protocols serves as a catalyst for change, setting new benchmarks for efficiency, agility, and resilience across the industry. This shift is not confined to any single segment-it permeates across operations, regulation, and market strategy, forging a more competitive and sustainable future for pharmaceutical manufacturing.

Key Segmentation Insights from an Evolving Marketplace

A nuanced understanding of market segmentation is essential for navigating the continuous manufacturing terrain. The segmentation analysis unpacks the market along various dimensions, each offering valuable insights into the drivers of production innovation and operational success. An examination based on components reveals a diversified approach that spans equipment, services, and software & control solutions. In this framework, equipment studies are further divided into specifics such as blenders, feeders, granulators, and reactors, ensuring that manufacturers target the most critical instruments necessary for seamless production flow.

A focus on technology types introduces another layer of differentiation, separating integrated continuous manufacturing systems from semi-continuous manufacturing systems. This distinction is pivotal, as it reflects the spectrum of technological maturity and the capability to adapt to specific operational requirements. Meanwhile, analysis according to formulations-encompassing liquid, semi-solid, and solid forms-provides a comprehensive lens through which manufacturers assess the suitability and flexibility of continuous processes for various product types.

Delineating the market by end-user activities further enhances this insight, distinguishing between contract manufacturing organizations and pharmaceutical companies. Each segment brings its own set of requirements and performance benchmarks, shaping the dialogue on quality, scalability, and cost-effectiveness. The segmentation is deepened through an examination of therapeutic areas, such as cardiovascular diseases, central nervous system disorders, infectious diseases, metabolic disorders, and oncology, illustrating how product specificity drives manufacturing innovation.

Finally, a detailed look at applications, including active pharmaceutical ingredients, biologics, and oral drugs, underscores the importance of aligning manufacturing technologies with product end-use and market demands. Together, these segmentation insights not only highlight the multiple facets of continuous manufacturing but also serve to guide strategic decision-making in an increasingly complex market landscape.

Based on Component, market is studied across Equipment, Services, and Software & Control Solutions. The Equipment is further studied across Blenders, Feeders, Granulators, and Reactors.

Based on Technology Type, market is studied across Integrated Continuous Manufacturing Systems and Semi-Continuous Manufacturing Systems.

Based on Formulations, market is studied across Liquid Formulations, Semi-solid Formulations, and Solid Formulations.

Based on End-user, market is studied across Contract Manufacturing Organizations and Pharmaceutical Companies.

Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases, Metabolic Disorders, and Oncology.

Based on Applications, market is studied across Active Pharmaceutical Ingredients, Biologics, and Oral Drugs.

Regional Trends and Insights Driving Global Change

The continuous manufacturing revolution is unfolding within a globally interconnected framework where regional dynamics play a critical role in shaping industry trends and policy directions. In the Americas, the focus has been on leveraging advanced technologies to streamline production processes and improve quality assurance. This region is characterized by a strong emphasis on regulatory compliance and innovation-driven growth, ensuring that pharmaceutical companies are well-equipped to meet both domestic and international quality standards.

Across Europe, the Middle East, and Africa, there is a prevailing synergy between tradition and technology, with legacy systems gradually giving way to more integrated, digitally enhanced production lines. In these regions, investment in infrastructure and research is propelling companies toward embracing continuous manufacturing processes with a strong commitment to sustainability and operational efficiency. The proactive governmental policies and regulatory frameworks have created an environment where innovation is not only encouraged but is viewed as essential for competitive survival.

The Asia-Pacific region, meanwhile, stands out as a dynamic hub of rapid industrial growth and technology adoption. Market players in this fast-evolving region are increasingly embracing continuous manufacturing as a means to meet surging demand and expand their capabilities in both domestic and international markets. Enhanced focus on research and development, coupled with robust economic expansion, has facilitated an environment ripe for the integration of continuous manufacturing practices.

Each region brings its unique strengths and challenges to the table, offering a rich tapestry of opportunities for those prepared to adapt to evolving market conditions. The interplay between technological advancement, regulatory support, and market demand across these regions accentuates the global trajectory towards an industry that values innovation, consistency, and operational excellence.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Evaluating Industry Leaders and Key Company Contributions

A myriad of influential companies has emerged at the forefront of continuous manufacturing, each contributing a distinct set of capabilities and innovations that are propelling the industry forward. Titans such as ABB Ltd, Amazon Web Services, Inc., and Capgemini SE have been instrumental in integrating sophisticated automation and digital solutions into the manufacturing landscape. Their contributions have enabled precision control and real-time data analytics, thereby ensuring that operational processes remain agile and secure.

Companies like Chemtrix BV by AGI Group and Continuus Pharmaceuticals have harnessed deep sector expertise to tailor their solutions to the unique demands of pharmaceutical production, focusing on efficient process design and robust scale-up mechanisms. In parallel, organizations such as Coperion GmbH and Corning Incorporated are recognized for their innovative engineering that supports the seamless integration of equipment and process optimization. Their advanced solutions improve overall production efficiency through meticulous design and long-term reliability.

Industry veterans like Emerson Electric Co. and Fette Compacting have further bolstered the market by offering robust hardware and integrated systems that ensure high-quality performance across diverse manufacturing environments. GEA Group AG and Gebruder Lodige Maschinenbau GmbH are notable for their significant investments in research and technological development, continuously pushing the envelope in design refinement and operational excellence. The specialized expertise provided by entities such as Glatt GmbH, Honeywell International, Inc., and Hosokawa Micron Corporation has catalyzed innovation in the pharmaceutical production line through bespoke control and automation systems.

Leaders like IMA Group, Korsch AG, L.B. Bohle Maschinen und Verfahren GmbH, and Pall Corporation by Danaher Corporation are widely acknowledged for their strategic contributions in advancing process reliability and efficiency. Companies including Repligen Corporation, Rockwell Automation Inc., and Scott Equipment Company have further demonstrated a deep commitment to quality leadership through their robust process solutions. Siemens AG, Syntegon Technology GmbH, and Thermo Fisher Scientific Inc. round out the list, showcasing the diverse blend of technical expertise and forward-thinking strategies that define the competitive edge in the continuous manufacturing space.

Collectively, these key players not only solidify the foundation of technological advancement in pharmaceutical manufacturing but also inspire ongoing innovation and investment in an industry poised for continued transformation.

The report delves into recent significant developments in the Pharmaceutical Continuous Manufacturing Market, highlighting leading vendors and their innovative profiles. These include ABB Ltd, Amazon Web Services, Inc., Capgemini SE, Chemtrix BV by AGI Group, Continuus Pharmaceuticals, Coperion GmbH, Corning Incorporated, Emerson Electric Co., Fette Compacting, GEA Group AG, Gebruder Lodige Maschinenbau GmbH, Glatt GmbH, Honeywell International, Inc., Hosokawa Micron Corporation, IMA Group, Korsch AG, L.B. Bohle Maschinen und Verfahren GmbH, Pall Corporation by Danaher Corporation, Repligen Corporation, Rockwell Automation Inc., Scott Equipment Company, Siemens AG, Syntegon Technology GmbH, and Thermo Fisher Scientific Inc.. Actionable Recommendations to Drive Industry Transformation

In light of the transformative innovations and dynamic market trends, industry leaders need to adopt targeted strategies to sustain competitive advantage and drive continuous improvement. One of the primary recommendations is to take an integrated approach toward technology deployment. Emphasizing the importance of setting up a robust digital infrastructure that integrates automated equipment with advanced control solutions is critical. Leaders must prioritize upfront investments in scalable technologies that ease future expansions while maintaining operational reliability.

Companies should also focus on process standardization and robust quality controls as they transition from batch to continuous manufacturing. Establishing a framework for continuous process monitoring and real-time data analytics will not only mitigate risks but also enable the proactive identification of potential inefficiencies. This approach calls for the convergence of operational technology and information technology in a manner that supports data-driven decision-making.

Considering market segmentation insights, it is essential to align technology choices with specific operational needs. Whether transitioning to integrated or semi-continuous systems, organizations should choose technologies that best match the product formulations and end-user requirements they serve. The assessment should encompass everything from the specific production equipment-blenders, feeders, granulators, and reactors-to the service and software layers that complement them.

In a rapidly evolving regulatory environment, investing in compliance and adaptability is an imperative. Regular review and adjustment of quality management systems, aligned with emerging global standards, will fortify operational resilience. Regional considerations also warrant strategic attention; companies should cultivate operational hubs that mirror regional strengths, be it the technological rigor of the Americas, the balanced regulatory support in Europe, Middle East and Africa, or the aggressive growth dynamics in Asia-Pacific.

Furthermore, fostering strategic collaborations with leading technology providers and process experts can propel operational excellence and innovation. Partnerships not only grant access to cutting-edge solutions and market insights but also provide a platform for shared risk management and development. This multidimensional approach-driven by investments in technology, process standardization, and strategic alliances-will enable industry leaders to navigate market fluctuations effectively and secure their role in the future of pharmaceutical manufacturing.

Conclusion: Embracing a Future of Continuous Innovation

The journey toward continuous manufacturing is emblematic of a broader shift in the pharmaceutical industry toward efficiency, innovation, and resilience. By harnessing state-of-the-art technologies and embracing digital integration, the industry is breaking free from traditional constraints and setting new benchmarks in product quality and operational agility.

This evolution is driven by a confluence of factors including evolving regulatory landscapes, technological advancements, and market pressures that demand faster and more reliable production processes. As organizations invest in training, infrastructure, and research and development, the benefits of continuous manufacturing become increasingly tangible through reduced production costs, enhanced product consistency, and a robust capacity for innovation.

Moreover, the emergence of varied market segmentation insights ensures that players at every level-from equipment operators and process engineers to strategic decision-makers-are better informed about where to focus their efforts. The collective industry shift, supported by consistent technological breakthroughs and market-driven adaptations, heralds a new era where collaborative innovation and operational excellence reign supreme.

Ultimately, the insights and trends discussed here illustrate that continuous manufacturing is not just a temporary innovation; it is a foundational shift that will continue to influence the landscape of pharmaceutical production for years to come. Leaders who embrace this change are poised to create agile, efficient, and future-ready manufacturing observatories that redefine global healthcare manufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases worldwide
      • 5.1.1.2. Growing need for efficient and reliable pharmaceutical production systems
      • 5.1.1.3. Regulatory support and incentives facilitating the adoption of continuous manufacturing in pharmaceutical industry
    • 5.1.2. Restraints
      • 5.1.2.1. High initial costs and scarcity of adequately trained professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in manufacturing technologies enabling real-time data monitoring and process optimization
      • 5.1.3.2. Surging investments and funding for the development of continuous manufacturing technology
    • 5.1.4. Challenges
      • 5.1.4.1. Technological limitations and complexity of continuous manufacturing processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: Efficiency in pharmaceutical continuous manufacturing of software & control solutions for continuous drug production
    • 5.2.2. Technology Type: Utilization of integrated continuous manufacturing systems due to high-quality products and reducing time and cost
    • 5.2.3. Formulations: Increasing usage of solid formulations due to personalization in drug delivery systems.
    • 5.2.4. End-user: Adoption of pharmaceutical companies to enhance production efficiency and control.
    • 5.2.5. Therapeutic Area: Rising usage of infectious diseases for enhancing agility and capacity in pharmaceutical production
    • 5.2.6. Applications: Expanding use of oral drugs for consistency and quality in drug formulation
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pharmaceutical Continuous Manufacturing Market, by Component

  • 6.1. Introduction
  • 6.2. Equipment
    • 6.2.1. Blenders
    • 6.2.2. Feeders
    • 6.2.3. Granulators
    • 6.2.4. Reactors
  • 6.3. Services
  • 6.4. Software & Control Solutions

7. Pharmaceutical Continuous Manufacturing Market, by Technology Type

  • 7.1. Introduction
  • 7.2. Integrated Continuous Manufacturing Systems
  • 7.3. Semi-Continuous Manufacturing Systems

8. Pharmaceutical Continuous Manufacturing Market, by Formulations

  • 8.1. Introduction
  • 8.2. Liquid Formulations
  • 8.3. Semi-solid Formulations
  • 8.4. Solid Formulations

9. Pharmaceutical Continuous Manufacturing Market, by End-user

  • 9.1. Introduction
  • 9.2. Contract Manufacturing Organizations
  • 9.3. Pharmaceutical Companies

10. Pharmaceutical Continuous Manufacturing Market, by Therapeutic Area

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. Central Nervous System Disorders
  • 10.4. Infectious Diseases
  • 10.5. Metabolic Disorders
  • 10.6. Oncology

11. Pharmaceutical Continuous Manufacturing Market, by Applications

  • 11.1. Introduction
  • 11.2. Active Pharmaceutical Ingredients
  • 11.3. Biologics
  • 11.4. Oral Drugs

12. Americas Pharmaceutical Continuous Manufacturing Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Pharmaceutical Continuous Manufacturing Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Pharmaceutical Continuous Manufacturing Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. STEERLife and Callidus partner to enhance global drug development
    • 15.3.2. Enzene launch EnzeneX 2.0 platform for enhanced biologics manufacturing at CPHI milan 2024
    • 15.3.3. Syntegon launch modular bioprocessing platform to streamline biopharmaceutical manufacturing
    • 15.3.4. Eli Lilly invests USD 1.8 billion in Irish manufacturing to advance pharmaceutical production
    • 15.3.5. Hovione and GEA partner to innovate continuous tableting technology
    • 15.3.6. Sartorius and Repligen launch integrated bioreactor system for enhanced biopharmaceutical production
    • 15.3.7. Sandoz partners with Just - Evotec biologics to expand biosimilar pipeline
    • 15.3.8. Arranta Bio sign contract with MIT to enhance continuous manufacturing of mRNA therapeutics
    • 15.3.9. Curia and Corning collaborate to innovate biopharmaceutical continuous flow manufacturing
    • 15.3.10. WuXi STA launch continuous manufacturing line for oral solid drugs in China
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. Syntegon Technology GmbH
    • 15.4.2. Siemens AG
    • 15.4.3. Chemtrix BV
    • 15.4.4. Emerson Electric Co.

Companies Mentioned

  • 1. ABB Ltd
  • 2. Amazon Web Services, Inc.
  • 3. Capgemini SE
  • 4. Chemtrix BV by AGI Group
  • 5. Continuus Pharmaceuticals
  • 6. Coperion GmbH
  • 7. Corning Incorporated
  • 8. Emerson Electric Co.
  • 9. Fette Compacting
  • 10. GEA Group AG
  • 11. Gebruder Lodige Maschinenbau GmbH
  • 12. Glatt GmbH
  • 13. Honeywell International, Inc.
  • 14. Hosokawa Micron Corporation
  • 15. IMA Group
  • 16. Korsch AG
  • 17. L.B. Bohle Maschinen und Verfahren GmbH
  • 18. Pall Corporation by Danaher Corporation
  • 19. Repligen Corporation
  • 20. Rockwell Automation Inc.
  • 21. Scott Equipment Company
  • 22. Siemens AG
  • 23. Syntegon Technology GmbH
  • 24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET MULTI-CURRENCY
  • FIGURE 2. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET MULTI-LANGUAGE
  • FIGURE 3. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 4. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY BLENDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FEEDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY GRANULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY REACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY SOFTWARE & CONTROL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY INTEGRATED CONTINUOUS MANUFACTURING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY SEMI-CONTINUOUS MANUFACTURING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY SEMI-SOLID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY SOLID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN PHARMA